SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.
A live webcast will be available in the Investors & Media section of the company’s website at www.septerna.com and will be archived for 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck
THRUST Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Carly Scaduto
Carly Scaduto Consulting
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$27.31 |
| Daily Change: | -0.31 -1.12 |
| Daily Volume: | 54,572 |
| Market Cap: | US$1.220B |
November 10, 2025 September 29, 2025 August 11, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
